Session Title: Vascular Diseases & Anterior/posterior segment surgery
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:08
Venue: Hall 3 (Level 0)
First Author: A.El Barky UNITED ARAB EMIRATES
The purpose of the study was to evaluate the effect of Focal Argon Subthreshold Laser Therapy in patients with chronic central serous Chorioretinopathy not responding to previous intravitreal Bevacizumab injections.
Sheikh Khalifa Medical City UAE
Cases included in this clinical trial were patients diagnosed with chronic central serous Chorioretinopathy more than 3 months in duration. All patients were previously treated with multiple intravitreal injections of off label Bevacizumab with no improvement in the visual acuity. The Mean number of injections was 2.37 ± 1.24. Sixteen patients were included in this study. Focal Argon laser treatment was done for all patients. At baseline all patients had best corrected visual acuity (BCVA) on the LogMAR scale, central macular thickness (CMT) measurement with spectral optical coherence tomography (OCT) Fluorescein angiography (FA) was done for all patients to locate the leakage site before laser therapy. Follow-up visits were done at 1, 3 and 6 months subsequent to laser treatment where BCVA and OCT measurements were recorded.
Of 16 patients with central serous Chorioretinopathy, 10 (62%) were men and 6(37.5%) were women with a mean age of 37.6 ± 3.9 years. The mean best-corrected visual acuity measurements improved significantly (P<0.001) from 0.39±0.45 LogMAR to a final best-corrected visual acuity of 0.09±0.42 LogMAR after laser therapy. The mean CMT measurements decreased significantly (P<0.001) from 554 μ±45 and at 6months was 274μ±34.
Focal argon subthreshold laser treatment improved the best-corrected visual acuity and reduced neurosensory detachment in patients with chronic central serous Chorioretinopathy not responding to previous intravitreal Bevacizumab injections.